携带中东呼吸综合征冠状病毒刺突糖蛋白的重组改良安卡拉痘苗病毒的保护效力
Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.
作者信息
Volz Asisa, Kupke Alexandra, Song Fei, Jany Sylvia, Fux Robert, Shams-Eldin Hosam, Schmidt Jörg, Becker Christin, Eickmann Markus, Becker Stephan, Sutter Gerd
机构信息
German Center for Infection Research (DZIF), Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Munich, Germany.
German Center for Infection Research (DZIF), Institute of Virology, Philipps University Marburg, Marburg, Germany.
出版信息
J Virol. 2015 Aug;89(16):8651-6. doi: 10.1128/JVI.00614-15. Epub 2015 May 27.
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory disease in humans. We tested a recombinant modified vaccinia virus Ankara (MVA) vaccine expressing full-length MERS-CoV spike (S) glycoprotein by immunizing BALB/c mice with either intramuscular or subcutaneous regimens. In all cases, MVA-MERS-S induced MERS-CoV-specific CD8(+) T cells and virus-neutralizing antibodies. Vaccinated mice were protected against MERS-CoV challenge infection after transduction with the human dipeptidyl peptidase 4 receptor. This MERS-CoV infection model demonstrates the safety and efficacy of the candidate vaccine.
摘要
中东呼吸综合征冠状病毒（MERS-CoV）可导致人类患上严重的呼吸道疾病。我们通过肌肉注射或皮下注射方案免疫BALB/c小鼠，对一种表达全长MERS-CoV刺突（S）糖蛋白的重组改良安卡拉痘苗病毒（MVA）疫苗进行了测试。在所有情况下，MVA-MERS-S均诱导产生了MERS-CoV特异性CD8(+) T细胞和病毒中和抗体。在用人类二肽基肽酶4受体转导后，接种疫苗的小鼠受到保护，免受MERS-CoV攻击感染。这种MERS-CoV感染模型证明了该候选疫苗的安全性和有效性。
相似文献
1
Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.
J Virol. 2015 Aug;89(16):8651-6. doi: 10.1128/JVI.00614-15. Epub 2015 May 27.
2
A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
J Virol. 2015 Nov;89(22):11654-67. doi: 10.1128/JVI.01815-15. Epub 2015 Sep 9.
3
CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice.
Viruses. 2018 Dec 16;10(12):718. doi: 10.3390/v10120718.
4
An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels.
Science. 2016 Jan 1;351(6268):77-81. doi: 10.1126/science.aad1283. Epub 2015 Dec 17.
5
Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.
PLoS One. 2019 Jul 22;14(7):e0220196. doi: 10.1371/journal.pone.0220196. eCollection 2019.
6
Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
J Virol. 2016 Dec 16;91(1). doi: 10.1128/JVI.01651-16. Print 2017 Jan 1.
7
The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
Vaccine. 2017 Jan 3;35(1):10-18. doi: 10.1016/j.vaccine.2016.11.064. Epub 2016 Nov 26.
8
DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice.
Vaccine. 2017 Apr 11;35(16):2069-2075. doi: 10.1016/j.vaccine.2017.02.063. Epub 2017 Mar 14.
9
Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice.
PLoS One. 2019 Oct 7;14(10):e0223684. doi: 10.1371/journal.pone.0223684. eCollection 2019.
10
MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
Vaccine. 2017 Mar 14;35(12):1586-1589. doi: 10.1016/j.vaccine.2017.02.012. Epub 2017 Feb 23.
引用本文的文献
1
Implementation of an Immunoassay Based on the MVA-T7pol-Expression System for Rapid Identification of Immunogenic SARS-CoV-2 Antigens: A Proof-of-Concept Study.
Int J Mol Sci. 2024 Oct 10;25(20):10898. doi: 10.3390/ijms252010898.
2
Mucosal immunity in upper and lower respiratory tract to MERS-CoV.
Front Immunol. 2024 Aug 30;15:1358885. doi: 10.3389/fimmu.2024.1358885. eCollection 2024.
3
Cold-adapted live attenuated MERS-CoV vaccine strain remains attenuated in mice after multiple passages in Vero cells at 37 °C.
Arch Microbiol. 2024 Sep 6;206(10):393. doi: 10.1007/s00203-024-04120-2.
4
DNA vaccine prime and replicating vaccinia vaccine boost induce robust humoral and cellular immune responses against MERS-CoV in mice.
Virol Sin. 2024 Jun;39(3):490-500. doi: 10.1016/j.virs.2024.05.005. Epub 2024 May 18.
5
Identification of a Spike-Specific CD8+ T-Cell Epitope Following Vaccination Against the Middle East Respiratory Syndrome Coronavirus in Humans.
J Infect Dis. 2024 Aug 16;230(2):e327-e332. doi: 10.1093/infdis/jiad612.
6
Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models.
Vaccines (Basel). 2023 May 21;11(5):1006. doi: 10.3390/vaccines11051006.
7
MERS-CoV‒Specific T-Cell Responses in Camels after Single MVA-MERS-S Vaccination.
Emerg Infect Dis. 2023 Jun;29(6):1236-1239. doi: 10.3201/eid2906.230128.
8
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases.
Signal Transduct Target Ther. 2023 Apr 7;8(1):149. doi: 10.1038/s41392-023-01408-5.
9
Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity.
J Clin Invest. 2022 Dec 15;132(24):e159895. doi: 10.1172/JCI159895.
10
Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications.
Vaccines (Basel). 2022 Sep 13;10(9):1516. doi: 10.3390/vaccines10091516.
本文引用的文献
1
Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease.
J Virol. 2015 Apr;89(7):3659-70. doi: 10.1128/JVI.03427-14. Epub 2015 Jan 14.
2
Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Lancet Infect Dis. 2014 Dec;14(12):1196-207. doi: 10.1016/S1473-3099(14)70963-6. Epub 2014 Oct 30.
3
Middle East respiratory syndrome coronavirus: epidemiology and disease control measures.
Infect Drug Resist. 2014 Nov 3;7:281-7. doi: 10.2147/IDR.S51283. eCollection 2014.
4
Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.
Vaccine. 2014 Oct 21;32(46):6170-6176. doi: 10.1016/j.vaccine.2014.08.086. Epub 2014 Sep 19.
5
Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice.
Vaccine. 2014 Oct 14;32(45):5975-82. doi: 10.1016/j.vaccine.2014.08.058. Epub 2014 Sep 3.
6
Middle East respiratory syndrome coronavirus: transmission and phylogenetic evolution.
Trends Microbiol. 2014 Oct;22(10):573-9. doi: 10.1016/j.tim.2014.08.001. Epub 2014 Aug 29.
7
Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.
Viruses. 2014 Jul 17;6(7):2735-61. doi: 10.3390/v6072735.
8
Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.
J Virol. 2014 Sep;88(18):10946-57. doi: 10.1128/JVI.00945-14. Epub 2014 Jul 9.
9
Calling for rapid development of a safe and effective MERS vaccine.
Microbes Infect. 2014 Jul;16(7):529-31. doi: 10.1016/j.micinf.2014.05.002. Epub 2014 Jun 12.
10
Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice.
Vaccine. 2014 May 30;32(26):3169-3174. doi: 10.1016/j.vaccine.2014.04.016. Epub 2014 Apr 13.
Zotero 插件